New medical device, Accuryn®, has potential to enhance reliability and decrease time required to measure intra-abdominal pressure
The prevalence of intra-abdominal hypertension (IAH) in the critically ill is reported to be as high as 50 percent and is a significant cause of abdominal compartment syndrome (ACS), morbidity and mortality.
Diagnosis requires an accurate, reliable and consistent standardized methodology for measuring intra-abdominal pressure (IAP). The accuracy of the intra-vesical pressure (IVP) method, the current standard-of-care measurement method, is hindered by “self-assembly” set-up, which is performed manually and introduces non-standardized construction, clinical technique and quality control challenges. It is often time-consuming, leads to errors and can put patients at risk for infection.
A recent study demonstrates a new method for automatically measuring IAP, the Accuryn Monitoring System, gives the same precision of accuracy as commercially-available methods while obtained more easily with a simple push of a button. Results will be shared at the 8th World Congress of the Abdominal Compartment Society meeting, June 15 – 17 in Banff, Alberta, Canada.
A benchtop study compared pressure measured by the Accuryn Monitoring System to a commercially available standard-of-care intra-vesical pressure (IVP) device. The Accuryn device had a higher measurement accuracy compared to the IVP device and the same precision compared to the IVP device across repeat measurements.
Dr. Daniel Burnett, chief executive officer of Potrero Medical, the maker of Accuryn, and adjunct professor at the University of California at San Francisco, “This study paves the way for industry discussions around the utility of continuous IAP monitoring. IAP measurements that accurately diagnose IAH and abdominal compartment syndrome historically have been significantly difficult to obtain. By simplifying the process and enhancing accuracy, Accuryn has the potential to guide earlier diagnoses and interventions to improve patient outcomes.”
The company has partnered with Potrero Medical, the maker of Accuryn, to bring the device to market and advance real-time monitoring for critically ill patients.